Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Drug Metabolism, Poor, CYP2C19-Related: early-phase trial registry
1 of 2 indexed Drug Metabolism, Poor, CYP2C19-Related trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Drug Metabolism, Poor, CYP2C19-Related: 2 US clinical trials tracked, 1 recruiting.
Drug Metabolism, Poor, CYP2C19-Related is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Genelex Corporation, running 1 of these trials.
Enrollment posture brief
Registry condition drug-metabolism-poor-cyp2c19-related
OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Drug Metabolism, Poor, CYP2C19-Related lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Drug Metabolism, Poor, CYP2C19-Related on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Drug Metabolism, Poor, CYP2C19-Related is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:
Mayo Clinic
NCT06322238
Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM
Genelex Corporation
NCT02428660
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Drug Metabolism, Poor, CYP2C19-Related records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Drug Metabolism, Poor, CYP2C19-Related trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Drug Metabolism, Poor, CYP2C19-Related page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Drug Metabolism, Poor, CYP2C19-Related trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Genelex Corporation sponsors the most Drug Metabolism, Poor, CYP2C19-Related trials on record, review their full trial history before evaluating a specific study. See Genelex Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Drug Metabolism, Poor, CYP2C19-Related condition card totals 2 registered trials; most-linked intervention Software-based drug & gene interaction risk analysis; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.